4sc Ag

4sc Discovery Gmbh

Panoptes Pharma Ges.m.b.h.

Roland Baumgartner

Johann Leban

Daniel Vitt

Stefan Tasler

Hella Kohlhof

Fritz Aberger

Wolfgang Gruber

Wael Saeb

Bernd Kramer

Carine Chevrier

Katharina Aulinger-Fuchs

Manfred Groeppel

The present invention relates to a DYRK1B inhibitor for use in the treatment of cancer, wherein in said cancer and/or in cells of said cancer the hedgehog signaling pathway is activated, and in particular the activation of the hedgehog signaling pathway is independent of signaling by the G protein-coupled receptor Smoothened.

Method of inhibiting DYRK1B

The present invention relates to compounds of the general formula (I), and the pharmaceutically acceptable salt or solvate thereof, as anti-inflammatory and immunomodulatory agents. 

IL17 and IFN-gamma inhibition for the treatment of autoimmune inflammation

The present invention relates to compounds of the general formula (I) and salts and physiologically functional derivatives thereof, for the use as a medicament.

Anti-inflammatory agents as virostatic compounds

The present invention provides a compound capable of binding to the ubiquinone binding site of DHODH which contains a non-aromatic ring system as a core structure, a group capable of interacting with structural elements of subsite 2 or 3 of the ubiquinone binding site of DHODH and a group capable of interacting hydrophobically with structural elements of subsite 1 of the ubiquinone binding site of DHODH. Furthermore, the present invention provides a compound capable of binding to the ubiquinone binding site of DHODH which contains an aromatic ring system as a core structure, a group capable of interacting with residues His 56 and/or Tyr 356 of subsite 3 of the ubiquinone binding site of DHODH and a group capable of interacting hydrophobically with structural elements of subsite 1 of the ubiquinone binding site of DHODH.

Method of identifying inhibitors of DHODH

Growing community of inventors

Planegg-Martinsried, Germany

Roland Baumgartner